WO2024063712A1 - Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients - Google Patents
Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients Download PDFInfo
- Publication number
- WO2024063712A1 WO2024063712A1 PCT/TR2022/051020 TR2022051020W WO2024063712A1 WO 2024063712 A1 WO2024063712 A1 WO 2024063712A1 TR 2022051020 W TR2022051020 W TR 2022051020W WO 2024063712 A1 WO2024063712 A1 WO 2024063712A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- fluticasone propionate
- homogenization
- suspending agent
- less
- Prior art date
Links
- 229960000289 fluticasone propionate Drugs 0.000 title claims abstract description 44
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title claims abstract description 44
- 239000000546 pharmaceutical excipient Substances 0.000 title claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 29
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 title description 17
- 229960004574 azelastine Drugs 0.000 title description 17
- 238000000265 homogenisation Methods 0.000 claims abstract description 40
- 239000000375 suspending agent Substances 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000007922 nasal spray Substances 0.000 claims description 20
- 229940097496 nasal spray Drugs 0.000 claims description 19
- 239000008213 purified water Substances 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 229960002714 fluticasone Drugs 0.000 claims description 13
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 6
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 229960002900 methylcellulose Drugs 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 25
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 14
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract description 8
- 208000036284 Rhinitis seasonal Diseases 0.000 abstract description 8
- 208000017022 seasonal allergic rhinitis Diseases 0.000 abstract description 7
- 229960004335 azelastine hydrochloride Drugs 0.000 abstract description 5
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 abstract description 5
- 238000002636 symptomatic treatment Methods 0.000 abstract description 5
- 239000000047 product Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 238000002156 mixing Methods 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 206010039085 Rhinitis allergic Diseases 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- -1 propionate ester Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- GEVMVZWOOIIINI-KTIJLCEXSA-N 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one;[(6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propano Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O GEVMVZWOOIIINI-KTIJLCEXSA-N 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940075416 dymista Drugs 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical class C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010039094 Rhinitis perennial Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229940045942 acetone sodium bisulfite Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 229940073555 nonoxynol-10 Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 229940093928 potassium nitrate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960005359 propylparaben sodium Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229960004599 sodium borate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Definitions
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastine hydrochloride and fluticasone propionate for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and older, wherein the suspending agent is used in certain weight, wherein the preparation process have a specific homogenization time and rate.
- Azelastine is a selective antihistamine
- Azelastine HCI has a chemical name as ( ⁇ )-l- (2H)-phthalazinone, 4-[(4-chlorophenyl) methyl] -2-(hexahydro- 1-methyl- lH-azepin-4-yl)- monohydrochloride and its chemical structure is shown in the Figure 1.
- Azelastine HCI is indicated for the relief of the symptoms of allergic rhinitis including seasonal allergic rhinitis and perennial allergic rhinitis for single therapy use.
- Azelastine hydrochloride has molecular weight of 521 g/mol, white to almost white crystalline powder.
- Fluticasone is a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. It is used in the form of its propionate ester for treatment of allergic rhinitis. It has a role as an anti ⁇ allergic agent and an anti-asthmatic drug.
- Fluticasone propionate is a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. It has a chemical name as S- (fluoromethyl)-6a,9-difluoro- 11 p, 17-dihydroxy- 16a-methyl-3-oxoandrosta- 1 , 4-diene- 17p- carbothioate, 17-propanoate and its chemical structure is shown in the Figure 2. Fluticasone propionate has a molecular weight of 500.6 g/mol with melting point 261-273 °C.
- Azelastine HC1 and fluticasone propionate combination has been used in EU with the trade name Dymista Nasal Spray and is indicated for seasonal allergic rhinitis.
- Complications that may be associated with allergic rhinitis include reduced quality of life, decreased concentration and focus problem, problems remembering things, sleep disorders, worsening asthma, more motor vehicle accidents, sinusitis and ear infection.
- nasal administration is an effective way of systemic delivery.
- Some of the critical points to nasal formulation process high water solubility, sufficient chemical stability, pleasant smell or taste, favourable nasal absorption parameters, minimum nasal irritation, low dose and non toxic metabolites.
- Nasal spray formulations may be water-based, hydroalcoholic, nonaqueous, suspensions, or emulsions.
- a formulation can include diverse excipients, including solvents, mucoadhesive agents, buffers, antioxidants, preservatives, and penetration enhancers (i.e., compounds to improve absorption or penetration).
- Specific properties of product development process for liquid preparations such as nasal spray are phyicochemical properties of active ingredient, vehicle, pH and buffer capacity, osmotic value, viscosity and appearance/smell/taste.
- Aqueous nasal preparations may comprise excipients; to adjust the viscosity or to adjust stabilise the pH value or to increase the solubility of active ingredient or to stabilise the preparation.
- Administration device for nasal route should be designed without contamination.
- viscosity One of the most important specifications for nasal sprays is viscosity. The main factors affected by viscosity are droplet size, droplet size distribution, penetration, bioequivalence etc. These factors are important for patient’s efficient use of medication.
- a spray pattern refers to the shape of a fluid that is released from a pressurized source such a nasal spray product. Spray pattern effects of results of droplet size distribution, penetration, bioequivalence etc.
- the one of the important issue is thatthe suspending agent quantity influences the spray pattern, suspending agent ratio in total composition is critical in present invention. Summary of the invention
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastine HCI and fluticasone propionate and one or more pharmaceutically acceptable excipients for the symptomatic treatment of seasonal allergic rhinitis, wherein the suspending agent in certain weight based on the total composition weight, wherein the preparation process have a specific homogenization time and rate.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastine HCI and fluticasone propionate and one or more pharmaceutically acceptable excipients for the symptomatic treatment of seasonal allergic rhinitis, wherein the suspending agent is used in % 1 to % 3 of total composition weight.
- a nasal spray composition comprising azelastin hydrochloride and fluticasone propionate as active ingredients, suspending agents, chelating agents, surfactants, solvents, preservatives and one or more pharmaceutically acceptable excipients, wherein the time and rate for homogenization stages for the manufacturing process are used in the following; a) Purified water and at least one suspending agent are mixed while homogenization is applied for 15 minutes or less with a speed 2000 rpm or less, b) Purified water and surfactant are mixed, and fluticasone propionate is added to the mixture, c) Fluticasone mixture obtained in step b is included into the mixture obtained in step a while second homogenization is applied for 30 minutes or less with a speed 1000 rpm or less.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin or pharmaceutically acceptable salts or esters thereof, fluticasone or pharmaceutically acceptable salts or esters thereof, and one or more pharmaceutically acceptable carriers or excipients.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin or pharmaceutically acceptable salts or esters thereof, fluticasone or pharmaceutically acceptable salts or esters thereof, and one or more pharmaceutically acceptable carriers or excipients, wherein the composition is used for the symptomatic treatment of seasonal allergic rhinitis.
- the present invention provides pharmaceutical compositions, comprising azelastine and/or one or more of its pharmacologically acceptable salts or esters thereof, particularly azelastine hydrochloride, and one or more pharmaceutically acceptable carriers or excipients.
- the present invention provides compositions, particularly pharmaceutical compositions, comprising fluticasone and/or one or more of its pharmacologically acceptable salts or esters thereof, particularly fluticasone propionate, and one or more pharmaceutically acceptable carriers or excipients.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastine hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable carriers or excipients, wherein the composition is administered as nasal sprey.
- the present invention relates to the preparation of a nasal spray compositions comprising
- the amount of suspending agent in the composition is from % 1 to %3 by weight to the total weight of the composition.
- a pharmaceutical composition comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the excipients are preferably suspending agents, chelating agents, surfactants, solvents, preservatives and other materials known to one of ordinary skill in the art and mixtures thereof.
- Suitable suspending agents according to the present invention are selected from the group including, but are not limited to xanthan gum, guar gum, microcrystalline cellulose, methylcellulose (MC), sodium carboxymethyl cellulose (CMC), and hydroxypropyl methylcellulose (HPMC) and other materials known to one of ordinary skill in the art and mixtures thereof.
- suspending agent can be a mixture of microcrystalline cellulose and carboxymethyl cellulose sodium. Mixture ratio of these materials can be selected in different percent.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the composition comprising a suspending agent.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the suspending agent is preferably a mix of microcrystalline cellulose and carboxymethyl cellulose sodium.
- this invention relates to a preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the suspending agent quantity in total composition is very critical to have optimum spray pattern values.
- suspending agent should be used in a total amount of 1 to 3% in weight based on the total composition weight,
- a pharmaceutical composition comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the excipients are selected from the group including, but are not limited to suspending agents, chelating agents, surfactants, solvents, buffers, antioxidants, penetration enhancers, antimicrobial preservatives and other materials known to one of ordinary skill in the art and mixtures thereof.
- Suitable chelating agents according to the present invention are selected from the group including, but are not limited to EDTA, disodium EDTA, citric acid and other materials known to one of ordinary skill in the art and mixtures thereof.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the chelating agent is preferably disodium EDTA.
- Suitable surfactants according to the present invention are selected from the group including, but are not limited to heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, polyoxyethylene stearate, polyoxyethylen sorbitan monolaurate, benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbates, for example polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80, sorbitan monopalmitate, sodium salts of fatty alcoholsulfates such as sodium lauryl sulfate, sodium dodecylsulfate, sodium salts of sulfosuccinates such as sodium dioctylsulfosuccinate, partially esters of fatty acids with alcohols such as glycerine monostearate, partially esters of fatty acids with sorbitans such as sorbitan monolaurate
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the surfactant is preferably polysorbate 80.
- Suitable solvents/cosolvents according to the present invention are selected from the group including, but are not limited to ethanol, polyethylene glycol, propylene glycol, isopropyl alcohol, purified water and other materials known to one of ordinary skill in the art and mixtures thereof.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the solvent is preferably purified water and the co-solvent is preferably glycerol.
- Suitable antimicrobial preservatives are selected from the group including, but are not limited to benzalkonium chloride, acetone sodium bisulfite, benzethonium chloride, benzoic acid, benzyl alcohol, boric acid, butylated hydroxyanisole, butylene glycol, calcium acetate, cetylpyridinium chloride, chlorhexidine, ethanol, glycerin, phenylethyl alcohol, phenoxyethanol, potassium metabisulfite, potassium nitrate, potassium sorbate, propionic acid, propylene glycol, propylparaben sodium, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium metabisulfite, sodium propionate, sodium sulfite, sorbic acid, zinc oxide, and N-acetylcysteine, and other materials known to one of ordinary skill in the art and mixtures thereof.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the antimicrobial preservative is preferably phenylethyl alcohol and/or benzalkonium chloride.
- Viscosity is one of the major criteria for nasal spray products. It effects spray pattern properties for nasal pharmaceutical product.
- the present invention relates to the preparation of pharmaceutical compositions by using homogenization steps.
- Homogenization step refers applied time and speed properties.
- the present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable carriers or excipients, wherein homogenization stages in the process are very critical to have optimal viscosity values.
- the present invention relates to the preparation of pharmaceutical compositions, while suspending agent and purified water mixing, homogenization is applied a certain time not exceeding 15 minutes, which speed not exceeding 2000 rpm.
- the present invention relates to the preparation of pharmaceutical compositions, after fluticasone propionate adding, homogenization should be applied a certain time not exceeding 30 minutes, which speed not exceeding 1000 rpm.
- the present invention relates to a process for preparing a nasal spray composition comprising azelastin hydrochloride, fluticasone propionate, at least one suspending agent, and one or more further pharmaceutically acceptable excipients, wherein the process comprises the steps of: a. Purified water and at least one suspending agent are mixed while homogenization is applied for 15 minutes or less with a speed 2000 rpm or less, b.
- Fluticasone mixture obtained in step b is included into the mixture obtained in step a while second homogenization is applied for 30 minutes or less with a speed 1000 rpm or less.
- allergic rhinitis will be understood to include “allergic” irritation and/or inflammation, including seasonal rhinitis (e.g. caused by outdoor agents such as pollen; hay fever) and/or perennial rhinitis (e.g. caused by house dust mites, indoor mold etc), as well as the symptoms thereof.
- seasonal rhinitis e.g. caused by outdoor agents such as pollen; hay fever
- perennial rhinitis e.g. caused by house dust mites, indoor mold etc
- Example 1 Azelastine HCl/Fluticasone Propionate 137 mcg/50 mcg Nasal Spray Unit
- a part of total purified water and suspending agent are mixed in the main tank. Along with mixing homogenization is also applied a certain time, homogenization speed not exceeding 2000 rpm.
- the mix of fluticasone propionate is taken in main tank. Also homogenization is applied a certain time, homogenization speed not exceeding 1000 rpm.
- the mix of fluticasone propionate is taken in main tank. Also homogenization is applied a certain time, homogenization speed not exceeding 1000 rpm.
- Antimicrobial preservative is added to the mix in the separate tank at an appropriate speed and time.
- An other antimicrobial preservative is added to the mix and keep mixing at an appropriate speed and time.
- the co-solvent is added to the mix and keep mixing at an appropriate speed and time. Then the separate tank content is transferred to the main tank. Remaining purified water is added lastly, so that final weight is completed and keep mixing at an appropriate speed and time.
- nasal corticosteroids such as fluticasone are effective in all symptoms of allergic rhinitis, their maximum efficacy begins in about 2 weeks.
- a combination of nasal corticosteroid such as fluticasone and antihistamine such as azelastine is preferred to relieve the patient in a short time.
- the present invention provides pharmaceutical composition comprising azelastin hydrochloride, fluticasone propionate and relevant excipients, characterized by i) A simple and exclusive manufacturing process ii) Stable formulation
- Nasal spray dosage form is cost-effective, easy to use and self-administrable, so it has high patient compliance.
- Viscosity test values for pharmaceutical nasal spray compositions are one of the essential parameters for process development and nasal spray manufacturing. The viscosity affects droplet size, droplet size distribution, penetration, bioequivalence etc. These factors are important for patient’s efficient use of medication.
- average viscosity value of reference product Dymista is between 35-40 cP.
- the two homogenization steps in the process are in the order described below.
- a part of total purified water and suspending agent are mixed in the main tank. Along with mixing homogenization is also applied a certain time, homogenization speed not exceeding 2000 rpm.
- the mix of fluticasone propionate is taken in main tank. Also homogenization is applied a certain time, homogenization speed not exceeding 1000 rpm.
- the mix of fluticasone propionate is taken in main tank. Also homogenization is applied a certain time, homogenization speed not exceeding 1000 rpm.
- Antimicrobial preservative is added to the mix in the separate tank at an appropriate speed and time.
- An other antimicrobial preservative is added to the mix and keep mixing at an appropriate speed and time.
- the co-solvent is added to the mix and keep mixing at an appropriate speed and time. Then the separate tank content is transferred to the main tank. Remaining purified water is added lastly, so that final weight is completed and keep mixing at an appropriate speed and time.
Abstract
The present invention relates to the preparation of pharmaceutical compositions comprising azelastine hydrochloride and fluticasone propionate for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and older, wherein the suspending agent is used in certain weight, wherein the preparation process have a specific homogenization time and rate.
Description
PHARMACEUTICAL COMPOSITIONS COMPRISING AZELASTINE HCI, FLUTICASONE PROPIONATE AND RELEVANT EXCIPIENTS
Field of the invention
The present invention relates to the preparation of pharmaceutical compositions comprising azelastine hydrochloride and fluticasone propionate for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and older, wherein the suspending agent is used in certain weight, wherein the preparation process have a specific homogenization time and rate.
Background of the invention
Azelastine is a selective antihistamine, and Azelastine HCI has a chemical name as (±)-l- (2H)-phthalazinone, 4-[(4-chlorophenyl) methyl] -2-(hexahydro- 1-methyl- lH-azepin-4-yl)- monohydrochloride and its chemical structure is shown in the Figure 1.
Figure 1
Azelastine HCI is indicated for the relief of the symptoms of allergic rhinitis including seasonal allergic rhinitis and perennial allergic rhinitis for single therapy use. Azelastine hydrochloride has molecular weight of 521 g/mol, white to almost white crystalline powder.
Fluticasone is a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. It is used in the form of its propionate ester for treatment of allergic rhinitis. It has a role as an anti ■■allergic agent and an anti-asthmatic drug.
Fluticasone propionate is a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. It has a chemical name as S- (fluoromethyl)-6a,9-difluoro- 11 p, 17-dihydroxy- 16a-methyl-3-oxoandrosta- 1 , 4-diene- 17p- carbothioate, 17-propanoate and its chemical structure is shown in the Figure 2. Fluticasone propionate has a molecular weight of 500.6 g/mol with melting point 261-273 °C.
Figure 2
Azelastine HC1 and fluticasone propionate combination has been used in EU with the trade name Dymista Nasal Spray and is indicated for seasonal allergic rhinitis.
Complications that may be associated with allergic rhinitis include reduced quality of life, decreased concentration and focus problem, problems remembering things, sleep disorders, worsening asthma, more motor vehicle accidents, sinusitis and ear infection.
Alternative to oral and intarvascular route, nasal administration is an effective way of systemic delivery. Some of the critical points to nasal formulation process: high water solubility, sufficient chemical stability, pleasant smell or taste, favourable nasal absorption parameters, minimum nasal irritation, low dose and non toxic metabolites.
Nasal spray formulations may be water-based, hydroalcoholic, nonaqueous, suspensions, or emulsions. A formulation can include diverse excipients, including solvents, mucoadhesive agents, buffers, antioxidants, preservatives, and penetration enhancers (i.e., compounds to improve absorption or penetration).
Specific properties of product development process for liquid preparations such as nasal spray are phyicochemical properties of active ingredient, vehicle, pH and buffer capacity, osmotic value, viscosity and appearance/smell/taste.
Aqueous nasal preparations may comprise excipients; to adjust the viscosity or to adjust stabilise the pH value or to increase the solubility of active ingredient or to stabilise the preparation. Administration device for nasal route should be designed without contamination.
One of the most important specifications for nasal sprays is viscosity. The main factors affected by viscosity are droplet size, droplet size distribution, penetration, bioequivalence etc. These factors are important for patient’s efficient use of medication.
Another important specification is spray pattern. A spray pattern refers to the shape of a fluid that is released from a pressurized source such a nasal spray product. Spray pattern effects of results of droplet size distribution, penetration, bioequivalence etc. The one of the important issue is thatthe suspending agent quantity influences the spray pattern, suspending agent ratio in total composition is critical in present invention.
Summary of the invention
The present invention relates to the preparation of pharmaceutical compositions comprising azelastine HCI and fluticasone propionate and one or more pharmaceutically acceptable excipients for the symptomatic treatment of seasonal allergic rhinitis, wherein the suspending agent in certain weight based on the total composition weight, wherein the preparation process have a specific homogenization time and rate.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastine HCI and fluticasone propionate and one or more pharmaceutically acceptable excipients for the symptomatic treatment of seasonal allergic rhinitis, wherein the suspending agent is used in % 1 to % 3 of total composition weight.
A nasal spray composition comprising azelastin hydrochloride and fluticasone propionate as active ingredients, suspending agents, chelating agents, surfactants, solvents, preservatives and one or more pharmaceutically acceptable excipients, wherein the time and rate for homogenization stages for the manufacturing process are used in the following; a) Purified water and at least one suspending agent are mixed while homogenization is applied for 15 minutes or less with a speed 2000 rpm or less, b) Purified water and surfactant are mixed, and fluticasone propionate is added to the mixture, c) Fluticasone mixture obtained in step b is included into the mixture obtained in step a while second homogenization is applied for 30 minutes or less with a speed 1000 rpm or less.
Detailed description of the invention
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin or pharmaceutically acceptable salts or esters thereof, fluticasone or pharmaceutically acceptable salts or esters thereof, and one or more pharmaceutically acceptable carriers or excipients.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin or pharmaceutically acceptable salts or esters thereof, fluticasone or pharmaceutically acceptable salts or esters thereof, and one or more pharmaceutically acceptable carriers or excipients, wherein the composition is used for the symptomatic treatment of seasonal allergic rhinitis.
The present invention provides pharmaceutical compositions, comprising azelastine and/or one or more of its pharmacologically acceptable salts or esters thereof, particularly azelastine hydrochloride, and one or more pharmaceutically acceptable carriers or excipients.
The present invention provides compositions, particularly pharmaceutical compositions, comprising fluticasone and/or one or more of its pharmacologically acceptable salts or esters thereof, particularly fluticasone propionate, and one or more pharmaceutically acceptable carriers or excipients.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastine hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable carriers or excipients, wherein the composition is administered as nasal sprey.
The present invention relates to the preparation of a nasal spray compositions comprising
• azelastin hydrochloride,
• fluticasone propionate,
• at least one suspending agent,
• and one or more further pharmaceutically acceptable excipients,
• wherein the amount of suspending agent in the composition is from % 1 to %3 by weight to the total weight of the composition.
Related to this invention, a pharmaceutical composition comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the excipients are preferably suspending agents, chelating agents, surfactants, solvents, preservatives and other materials known to one of ordinary skill in the art and mixtures thereof.
Suitable suspending agents according to the present invention are selected from the group including, but are not limited to xanthan gum, guar gum, microcrystalline cellulose, methylcellulose (MC), sodium carboxymethyl cellulose (CMC), and hydroxypropyl methylcellulose (HPMC) and other materials known to one of ordinary skill in the art and mixtures thereof.
In one embodiment, suspending agent can be a mixture of microcrystalline cellulose and carboxymethyl cellulose sodium. Mixture ratio of these materials can be selected in different percent.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the composition comprising a suspending agent.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the suspending agent is preferably a mix of microcrystalline cellulose and carboxymethyl cellulose sodium.
In one embodiment, this invention relates to a preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the suspending agent quantity in total composition is very critical to have optimum spray pattern values.
Relating to this embodiment, suspending agent should be used in a total amount of 1 to 3% in weight based on the total composition weight,
The pharmaceutical composition according to this invention, wherein the suspending agent is used from % 1 to % 3 of total composition weight, and preferably from % 1,5 to % 2,5 (w/w).
In this invention, a pharmaceutical composition comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the excipients are selected from the group including, but are not limited to suspending agents, chelating agents, surfactants, solvents, buffers, antioxidants, penetration enhancers, antimicrobial preservatives and other materials known to one of ordinary skill in the art and mixtures thereof.
Suitable chelating agents according to the present invention are selected from the group including, but are not limited to EDTA, disodium EDTA, citric acid and other materials known to one of ordinary skill in the art and mixtures thereof.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the chelating agent is preferably disodium EDTA.
Suitable surfactants according to the present invention are selected from the group including, but are not limited to heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, polyoxyethylene stearate, polyoxyethylen sorbitan monolaurate, benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbates, for example polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80, sorbitan monopalmitate, sodium salts of fatty alcoholsulfates such as sodium lauryl sulfate, sodium dodecylsulfate, sodium salts of sulfosuccinates such as sodium dioctylsulfosuccinate, partially esters of fatty acids with alcohols such as glycerine monostearate, partially esters of fatty acids with sorbitans such as sorbitan monolaurate, partially esters of fatty acids with polyhydroxyethylene sorbitans such as polyethyleneglycol sorbitan monolaurate, - monostearate or -monooleate, ethers of fatty alcohols with polyhydroxyethylene, esters of fatty acids with polyhydroxyethylene, copolymers of ethylenoxide and propylenoxide (Pluronic®) and ethoxylated triglycerides and other materials known to one of ordinary skill in the art and mixtures thereof.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the surfactant is preferably polysorbate 80.
Suitable solvents/cosolvents according to the present invention are selected from the group including, but are not limited to ethanol, polyethylene glycol, propylene glycol, isopropyl alcohol, purified water and other materials known to one of ordinary skill in the art and mixtures thereof.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the solvent is preferably purified water and the co-solvent is preferably glycerol.
Suitable antimicrobial preservatives according to the present invention are selected from the group including, but are not limited to benzalkonium chloride, acetone sodium bisulfite, benzethonium chloride, benzoic acid, benzyl alcohol, boric acid, butylated hydroxyanisole, butylene glycol, calcium acetate, cetylpyridinium chloride, chlorhexidine, ethanol, glycerin, phenylethyl alcohol, phenoxyethanol, potassium metabisulfite, potassium nitrate, potassium sorbate, propionic acid, propylene glycol, propylparaben sodium, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium metabisulfite, sodium propionate, sodium sulfite, sorbic acid, zinc oxide, and N-acetylcysteine, and other materials known to one of ordinary skill in the art and mixtures thereof.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable excipients, wherein the antimicrobial preservative is preferably phenylethyl alcohol and/or benzalkonium chloride.
Determined process steps are very critical in this invention. To optain optimum properties for a nasal spray product, process steps should be decided carefully.
Viscosity is one of the major criteria for nasal spray products. It effects spray pattern properties for nasal pharmaceutical product.
The present invention relates to the preparation of pharmaceutical compositions by using homogenization steps. Homogenization step refers applied time and speed properties.
The present invention relates to the preparation of pharmaceutical compositions comprising azelastin hydrochloride, fluticasone propionate, and one or more pharmaceutically acceptable carriers or excipients, wherein homogenization stages in the process are very critical to have optimal viscosity values.
Adding suspending agent and adding fluticasone propionate stages are crucial. At these stages, homogenization properties should be adjusted to have optimum viscosity values.
The present invention relates to the preparation of pharmaceutical compositions, while suspending agent and purified water mixing, homogenization is applied a certain time not exceeding 15 minutes, which speed not exceeding 2000 rpm.
The present invention relates to the preparation of pharmaceutical compositions, after fluticasone propionate adding, homogenization should be applied a certain time not exceeding 30 minutes, which speed not exceeding 1000 rpm.
In this invention, while suspending agent and purified water are mixing at the beginning of preparing process, homogenization is applied a certain time, which speed not exceeding 2000 rpm. And after fluticasone propionate is added to the mix, homogenization should be applied again which speed not exceeding 1000 rpm.
The present invention relates to a process for preparing a nasal spray composition comprising azelastin hydrochloride, fluticasone propionate, at least one suspending agent, and one or more further pharmaceutically acceptable excipients, wherein the process comprises the steps of: a. Purified water and at least one suspending agent are mixed while homogenization is applied for 15 minutes or less with a speed 2000 rpm or less, b. Purified water and surfactant are mixed, and fluticasone propionate is added to the mixture, c. Fluticasone mixture obtained in step b is included into the mixture obtained in step a while second homogenization is applied for 30 minutes or less with a speed 1000 rpm or less.
In this invention, the term "allergic rhinitis" will be understood to include “allergic” irritation and/or inflammation, including seasonal rhinitis ( e.g. caused by outdoor agents such as pollen; hay fever) and/or perennial rhinitis ( e.g. caused by house dust mites, indoor mold etc), as well as the symptoms thereof.
The present pharmaceutical composition is described in the following example in more details. This example is not limiting the scope of the present invention and is to be considered accordingly foregoing detailed description.
Example 1: Azelastine HCl/Fluticasone Propionate 137 mcg/50 mcg Nasal Spray Unit Formula
The process for the preparation of Azelastine HCl/Fluticasone Propionate 137 mcg/50 mcg nasal sprey according to the following process:
Stage 1 with homogenization:
A part of total purified water and suspending agent are mixed in the main tank. Along with mixing homogenization is also applied a certain time, homogenization speed not exceeding 2000 rpm.
Stage 2:
Some purified water in a certain percentage is taken in a separate tank and mixed with surfactant agent. Then fluticasone propionate is added to the mix and keep mixing at an appropriate speed and time.
Stage 3 with homogenization:
The mix of fluticasone propionate is taken in main tank. Also homogenization is applied a certain time, homogenization speed not exceeding 1000 rpm.
Stage 4:
The mix of fluticasone propionate is taken in main tank. Also homogenization is applied a certain time, homogenization speed not exceeding 1000 rpm.
Some purified water in a certain percentage is taken in a separate tank and mixed with chelating agent. Antimicrobial preservative is added to the mix in the separate tank at an appropriate speed and time. An other antimicrobial preservative is added to the mix and keep mixing at an appropriate speed and time.
After adding azelastine HC1 to the mix in the separate tank, the co-solvent is added to the mix and keep mixing at an appropriate speed and time. Then the separate tank content is transferred to the main tank. Remaining purified water is added lastly, so that final weight is completed and keep mixing at an appropriate speed and time.
Advantages
Instead of using two separate products of azelastin and fluticasone for use in the treatment, it is provided patient compliance who received the required amount pharmaceutically with single azelastin and fluticasone combination product.
Although nasal corticosteroids such as fluticasone are effective in all symptoms of allergic rhinitis, their maximum efficacy begins in about 2 weeks. A combination of nasal corticosteroid such as fluticasone and antihistamine such as azelastine is preferred to relieve the patient in a short time.
For the treatment of allergic rhinitis, a synergistic effect is expected for a more effective treatment in short time using with the combination of azelastine and fluticasone active ingredients, which were previously used in mono form in the treatment of allergic rhinitis.
The present invention provides pharmaceutical composition comprising azelastin hydrochloride, fluticasone propionate and relevant excipients, characterized by i) A simple and exclusive manufacturing process ii) Stable formulation
Nasal spray dosage form is cost-effective, easy to use and self-administrable, so it has high patient compliance.
When the spray pattern test results of the pharmaceutical composition performed, it has been observed that optimum spray pattern value is achieved by using the suspending agent in a certain ratio to the total composition weight. This ratio is 1-3% in weight based on the total composition weight. Preferably, 1,5-2.5% in weight based on the total composition weight.
According to the viscosity test results, it is obtained also optimum viscosity value for pharmaceutical composition comprising azelastin hydrochloride, fluticasone propionate active ingredients, by using a homogenizer during the manufacturing process at certain stages and in a certain period of time.
Viscosity tests
Viscosity test values for pharmaceutical nasal spray compositions are one of the essential parameters for process development and nasal spray manufacturing. The viscosity affects droplet size, droplet size distribution, penetration, bioequivalence etc. These factors are important for patient’s efficient use of medication.
General properties of relevant batches (reference product and test product) are shown in Table2.
Table 2: Summary of Batches Used in Viscosity Tests
The results of Dymista - 137 mcg/50 mcg Nasal Spray (Reference product) and Azelastine HCl/Fluticasone Propionate - 137 mcg/50 mcg Nasal Spray (Test product) are compared.
Table 3: Average Viscosity Results for Dymista-137 mcg/50 mcg Nasal Spray (Reference Product)
According to the test results, average viscosity value of reference product Dymista is between 35-40 cP. To achieve similar viscosity results also in test product, attention should be paid to homogenization stage in the manufacturing process. The two homogenization steps in the process are in the order described below.
Stage 1 with homogenization:
A part of total purified water and suspending agent are mixed in the main tank. Along with mixing homogenization is also applied a certain time, homogenization speed not exceeding 2000 rpm.
Stage 2:
Some purified water in a certain percentage is taken in a separate tank and mixed with surfactant agent. Then fluticasone propionate is added to the mix and keep mixing at an appropriate speed and time.
Stage 3 with homogenization:
The mix of fluticasone propionate is taken in main tank. Also homogenization is applied a certain time, homogenization speed not exceeding 1000 rpm.
Stage 4:
The mix of fluticasone propionate is taken in main tank. Also homogenization is applied a certain time, homogenization speed not exceeding 1000 rpm.
Some purified water in a certain percentage is taken in a separate tank and mixed with chelating agent. Antimicrobial preservative is added to the mix in the separate tank at an appropriate speed and time. An other antimicrobial preservative is added to the mix and keep mixing at an appropriate speed and time.
After adding azelastine HC1 to the mix in the separate tank, the co-solvent is added to the mix and keep mixing at an appropriate speed and time. Then the separate tank content is transferred to the main tank. Remaining purified water is added lastly, so that final weight is completed and keep mixing at an appropriate speed and time.
In this invention, viscosity testing for test product has been performed at regular intervals during keeping the final mix on hold for a week.
Table 4: Average Viscosity Results for Azelastine HCl/Fluticasone Propionate- 137 mcg/50 mcg Nasal Spray (Test Product)
As the homogenization time and rate in the manufacturing process decreases, the viscosity values of test product approaches the viscosity values of reference product Dymista.
Claims
1. A nasal spray composition comprising
• azelastin hydrochloride,
• fluticasone propionate,
• at least one suspending agent, and
• one or more further pharmaceutically acceptable excipients,
• wherein the amount of suspending agent in the composition is from % 1 to %3 by weight to the total weight f the composition.
2. The composition according to claim 1, wherein at least one suspending agent is selected from the group consisting of xanthan gum, guar gum, microcrystalline cellulose, methylcellulose (MC), sodium carboxymethyl cellulose (CMC), and hydroxypropyl methylcellulose (HPMC) and a mixture of microcrystalline cellulose and carboxymethylcellulose sodium.
3. The composition according to any one of the previous claims, wherein the composition comprises two suspending agents.
4. The composition according to any one of the previous claims, wherein the composition comprises microcrystalline cellulose and carboxymethyl cellulose sodium as suspending agents.
5. The composition according to any one of the previous claims, wherein the amount of suspending agent in the composition is from %1,5 to %2,5 by weight to the total weight f the composition.
6. The composition according to any one of the previous claims, wherein the composition is prepared by using homogenization stages which comprise a. At least one suspending agent and purified water are mixed while homogenization is applied for 15 minutes or less with a speed 2000 rpm or less, and b. After adding the fluticasone propionate to the mixture second homogenization is applied for 30 minutes or less with a speed 1000 rpm or less.
7. A process for preparing a nasal spray composition comprising azelastin hydrochloride, fluticasone propionate, at least one suspending agent, and one or more further pharmaceutically acceptable excipients, wherein the process comprises the steps of: a. Purified water and at least one suspending agent are mixed while homogenization is applied for 15 minutes or less with a speed 2000 rpm or less, b. Purified water and surfactant are mixed, and fluticasone propionate is added to the mixture, c. Fluticasone mixture obtained in step b is included into the mixture obtained in step a while second homogenization is applied for 30 minutes or less with a speed 1000 rpm or less.
8. A process according to claim 7, wherein at least one suspending agent is selected from the group consisting of xanthan gum, guar gum, microcrystalline cellulose, methylcellulose (MC), sodium carboxymethyl cellulose (CMC), and hydroxypropyl methylcellulose (HPMC) and a mixture of microcrystalline cellulose and carboxymethylcellulose sodium.
9. A process according to any one of the previous claims 7-8, wherein step a comprises two suspending agents.
10. A process according to any one of the previous claims 7-10, wherein step a comprises comprises microcrystalline cellulose and carboxymethyl cellulose sodium as suspending agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2022/051020 WO2024063712A1 (en) | 2022-09-20 | 2022-09-20 | Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2022/051020 WO2024063712A1 (en) | 2022-09-20 | 2022-09-20 | Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024063712A1 true WO2024063712A1 (en) | 2024-03-28 |
Family
ID=90454890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2022/051020 WO2024063712A1 (en) | 2022-09-20 | 2022-09-20 | Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024063712A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2389530A (en) * | 2002-06-14 | 2003-12-17 | Cipla Ltd | Pharmaceutical composition comprising azelastine and steroid |
| CN106806342A (en) * | 2015-12-01 | 2017-06-09 | 四川海思科制药有限公司 | A kind of azelastine hydrochloride fluticasone propionate nasal spray pharmaceutical composition and preparation method thereof |
| CN109288790A (en) * | 2017-07-25 | 2019-02-01 | 健乔信元医药生技股份有限公司 | Nasal pharmaceutical composition and preparation method thereof |
-
2022
- 2022-09-20 WO PCT/TR2022/051020 patent/WO2024063712A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2389530A (en) * | 2002-06-14 | 2003-12-17 | Cipla Ltd | Pharmaceutical composition comprising azelastine and steroid |
| CN106806342A (en) * | 2015-12-01 | 2017-06-09 | 四川海思科制药有限公司 | A kind of azelastine hydrochloride fluticasone propionate nasal spray pharmaceutical composition and preparation method thereof |
| CN109288790A (en) * | 2017-07-25 | 2019-02-01 | 健乔信元医药生技股份有限公司 | Nasal pharmaceutical composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| LE, V. N. P. ET AL.: "Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate", AAPS PHARMSCITECH, vol. 13, 2012, pages 477 - 484, XP035064294, DOI: 10.1208/s12249-012-9765-8 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3421348B2 (en) | Stable budezonide solution, process for producing the same and use of the solution as an enema and pharmaceutical foam | |
| US8647665B2 (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application | |
| JP5721927B2 (en) | Topical composition containing at least one vitamin D or one vitamin D analog and at least one corticosteroid | |
| US8980290B2 (en) | Transdermal compositions for anticholinergic agents | |
| KR101777157B1 (en) | Aqueous clear solutions of Fluocinolone Acetonide for treatment of otic inflammation | |
| US20110105450A1 (en) | Ophthalmic formulations of fluticasone and methods of use | |
| JP2011508776A (en) | Stable aqueous cyclosporine composition | |
| US20070099883A1 (en) | Anhydrous mometasone furoate formulation | |
| US20120022032A1 (en) | Corticosteroid compositions and methods of treatments thereof | |
| EP2120868A2 (en) | Low-dose mometasone formulations | |
| WO2004082590A2 (en) | A low dose corticosteroid composition | |
| WO2020141472A1 (en) | Nebulization composition comprising tiotropium and indacaterol | |
| JP2011507895A (en) | Enhanced light stabilization of oxymetazoline | |
| WO2024063712A1 (en) | Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients | |
| JP2002526423A (en) | Oxybutynin formulations and methods of use | |
| US20230181555A1 (en) | Stable and preserved pharmaceutical compositions of bilastine | |
| US11642309B2 (en) | Aqueous compositions comprising bilastine and mometasone | |
| JP2841714B2 (en) | Long-acting nasal drops | |
| WO2022098319A1 (en) | Pharmaceutical compositions comprising azelastine, beclomethasone and relevant excipients | |
| US11642324B1 (en) | Topical tranexamic acid compositions and methods of use thereof | |
| WO2022003168A1 (en) | Topical gel formulation containing asimadoline | |
| JPH10316572A (en) | Loteprednol etabonate aqueous suspension | |
| CN117813117A (en) | Repentinib composition and application thereof | |
| JP2002020284A (en) | Eye lotion | |
| KR20150128952A (en) | Topical compositions of flunisolide and methods of treatment |